Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The eastern cooperative oncology group results

Medicine & Life Sciences

• piroxantrone 100%
• merbarone 94%
• Paclitaxel 49%
• Non-Small Cell Lung Carcinoma 43%
• Intravenous Infusions 11%
• Intercalating Agents 6%
• Survival Rate 6%
• aniline 5%
• Topoisomerase II Inhibitors 5%
• Anthraquinones 5%
• thiobarbituric acid 5%
• Premedication 4%
• Drug Therapy 4%
• Cardiotoxicity 4%
• DNA 4%
• Survival 4%
• Leukopenia 4%
• Anaphylaxis 4%
• Granulocyte Colony-Stimulating Factor 4%
• Animals 4%
• Mitosis 3%
• Therapeutics 3%
• Cell Division 3%
• Catheters 3%
• Poisons 2%
• Neoplasms 2%
• Growth 2%
• In Vitro Techniques 1%